Prescription Drugs - Research and Data from KFF

How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market

Jun 11, 2026

Issue Brief

The private plans that offer the Medicare Part D benefit - stand-alone drug plans and Medicare Advantage drug plans - are increasingly are competing on uneven terms, in part because the payment system for Medicare Advantage plans enables them to lower Part D premiums or reduce Part D cost sharing, making drug coverage from Medicare Advantage plans appear considerably cheaper, or even premium-free, to the beneficiary. This brief discusses the growing instability of the Part…

Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026

Jun 11, 2026

Issue Brief

The Medicare Part D program provides an outpatient prescription drug benefit to 56 million older adults and people with long-term disabilities in Medicare who enroll in private plans. This brief analyzes Medicare Part D enrollment, premiums, and cost sharing in 2026 and trends over time, based on data from the Centers for Medicare & Medicaid Services (CMS).

As TrumpRx Expands to Include Generic Drugs, KFF Polling Shows Nearly 6 in 10 Adults Are Worried About Prescription Drug Costs

May 18, 2026

Quick Insights

As of early March, a majority of the public (59%) is worried about affording prescription drugs for themselves and their families, the largest share since KFF first polled this question in 2018.

What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge

May 11, 2026

Issue Brief

This brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare & Medicaid Services’ (CMS) efforts to expand access and lower costs for GLP-1s through temporary demonstration programs including the BALANCE Model, and potential impacts on beneficiaries and program budgets.

A Look at the GENEROUS Model and Factors That Could Impact Medicaid Drug Costs

May 8, 2026

Issue Brief

This issue brief provides background on the GENEROUS model, examines the factors that will contribute to the model’s overall impact on Medicaid drug costs, and illustrates how savings will depend on model details that are confidential or uncertain at this time.

MAHA Health Concerns Resonate Broadly but Lag Behind Health Care Costs Even for MAHA Voters

May 6, 2026

News Release

Chemical food additive and pesticide concerns associated with the Make America Health Again (MAHA) movement are shared broadly across the public. But when it comes to voters, health care costs are a higher priority and bigger motivator, even among MAHA supporters, a new KFF Health Tracking Poll finds.

KFF Health Tracking Poll: MAHA and the Midterms

May 6, 2026

Poll Finding

This KFF Health Tracking Poll finds that the cost of health care is a more prominent focus for Make America Healthy Again (MAHA) voters than issues like food and vaccine policy. Four in ten MAHA voters (42%) choose lowering health costs as the most important health priority, outranking other MAHA priorities.

Number of Medicare Stand-alone Prescription Drug Plans (PDPs)

Apr 10, 2026

State Health Facts Indicator

Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied

Apr 2, 2026

Quick Insights

Certain insurers must now publicly report specific prior authorization metrics, but the new data offer limited insight, providing no information on what types of services are being approved and denied or why as well as no data on prescription drugs.

Public Opinion on Prescription Drugs and Their Prices

Mar 31, 2026

Poll Finding

This chart collection draws on recent KFF poll findings to provide an in-depth look at the public's attitudes toward prescription drugs and their prices. Results include the U.S. public’s experiences with prescription drug costs, use of GLP-1 medications, and support for policy solutions.

Topics

Policy Research

Polling

Health News

Data & Features

For Media

About

View the Latest: Prescription Drugs

Filter